GlassScriptPhysician profile
William W Richardson
NPI 1649231424
$40,029.00
in general payments reported to CMS, 2019-2025
32 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $483 · 2021: $1,508 · 2022: $1,978 · 2023: $1,062 · 2024: $34K · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $33K · Food and Beverage: $2,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $32,571.00 |
| Food and Beverage | $2,449.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Skye Orthobiologics LLC | $32,571.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $871.55 | 2019-2024 | Brilinta, Wainua |
| Janssen Pharmaceuticals, INC | $833.82 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $771.91 | 2019-2024 | |
| Cvrx, INC. | $727.95 | 2020-2024 | Barostim Neo System |
| Biotronik INC. | $628.00 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $614.07 | 2021-2025 | Verquvo |
| Amgen INC. | $440.25 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.90 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $292.51 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.12 | 2019-2024 | Lifevest |
| Novo Nordisk INC | $210.99 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $191.94 | 2023-2024 | Inpefa |
| Pfizer INC. | $181.74 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $159.63 | 2022-2024 | Onpattro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $146.55 | 2019-2024 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $129.03 | 2024-2025 | |
| Esperion Therapeutics, INC. | $112.79 | 2021-2024 | Nexletol |
| Kestra Medical Technology Services, INC. | $89.47 | 2023-2025 | Assure Wcd |
| Boston Scientific Corporation | $72.89 | 2019-2021 | |
| Abbott Laboratories | $68.17 | 2025 | Aveir, Jot Dx |
| Edwards Lifesciences Corporation | $34.87 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $34.01 | 2021 | |
| Janssen Biotech, INC. | $29.19 | 2025 | Tremfya |
| Philips North America LLC | $27.18 | 2023 | |
| Ge Healthcare | $25.54 | 2020 | |
| Vyne Pharmaceuticals INC. | $21.81 | 2020 | |
| Mannkind Corporation | $18.50 | 2025 | |
| Dusa Pharmaceuticals, INC. | $17.47 | 2019 | |
| Astellas Pharma US INC | $15.84 | 2019 | |
| Genzyme Corporation | $15.04 | 2024 | |
| Braemar Manufacturing, LLC | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.